Report an error

Spotted something inaccurate in “Eplontersen Shows Benefit Only as Monotherapy in ATTR-CM Phase 3 Trial; No Added Benefit With Tafamidis”? Tell us what’s wrong and we’ll check it against the original source.

Website

Send report Cancel

This form is for factual corrections. We read every report but cannot reply individually.